JAK-IN-23

JAK-IN-23 is an orally active double inhibitor of JAK/STAT and NF-κB. JAK-IN-23 can inhibit JAK1/2/3 with IC50 values of 8.9 nM, 15 nM and 46.2 nM, respectively. JAK-IN-23 has potent inhibitory activities against interferon-stimulated genes (ISG) and NF-κB pathways with IC50 values of 3.3 nM and 150.7 nM, respectively. JAK-IN-23 has great anti-inflammatory that decreases the release of various proinflammatory factors. JAK-IN-23 can be used for the research of inflammatory bowel disease (IBD) [1].

Product Specifications

CAS Number

[3031837-35-8]

UNSPSC

12352005

Target

JAK; NF-κB; STAT; STING

Type

Reference compound

Related Pathways

Epigenetics; Immunology/Inflammation; JAK/STAT Signaling; NF-κB; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/jak-in-23.html

Purity

98.88

Solubility

DMSO : 5 mg/mL (ultrasonic; warming; heat to 80°C)

Smiles

OC1=C(Cl)C=C(C2=CC=C3N=CC(N=C(C)N4C5CCN(C)CC5)=C4C3=C2)C=C1Cl

Molecular Formula

C23H22Cl2N4O

Molecular Weight

441.35

References & Citations

[1]Xuewu Liang, et al. Discovery of Novel Imidazo[4,5- c]quinoline Derivatives to Treat Inflammatory Bowel Disease (IBD) by Inhibiting Multiple Proinflammatory Signaling Pathways and Restoring Intestinal Homeostasis. J Med Chem. 2022 Sep 2.